» Articles » PMID: 30592279

Protective Effect of Dihydromyricetin Revents Fatty Liver Through Nuclear Factor‑κB/p53/B‑cell Lymphoma 2‑associated X Protein Signaling Pathways in a Rat Model

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2018 Dec 29
PMID 30592279
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Dihydromyricetin is the major flavonoid in vine tea, whose pharmacological action has attracted increasing attention in recent years. The triglyceride, albumin (ALB), alanine aminotransferase, aspartate aminotransferase, malondialdehyde, superoxide dismutase, glutathione (GSH), GSH peroxidase, tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6 and IL‑18 expression levels were measured using enzyme‑linked immunosorbent assay kits. The protein levels of ALB and collagen I, PPARα, NF‑κB, p53 and Bax were used to measure using western blotting. The results revealed that dihydromyricetin prevented the development of fatty liver, and inhibited oxidative stress, inflammation and apoptosis in a fatty liver rat model. In addition, treatment with dihydromyricetin inhibited the levels of ALB and collagen I, while it induced peroxisome proliferator‑activated receptor α protein expression. Dihydromyricetin also suppressed the protein expression levels of nuclear factor (NF)‑κB, p53 and B‑cell lymphoma 2‑associated X protein (Bax) in the rat model. Collectively, it is concluded that dihydromyricetin exerted a protective effect on fatty liver through NF‑κB/p53/Bax signaling pathways in a rat model.

Citing Articles

Multiple molecular and cellular mechanisms of the antitumour effect of dihydromyricetin (Review).

Xia T, Zhu R Biomed Rep. 2024; 20(5):82.

PMID: 38628627 PMC: 11019658. DOI: 10.3892/br.2024.1769.


Dihydromyricetin alleviates inflammatory bowel disease associated intestinal fibrosis by inducing autophagy through the PI3K/AKT/mTOR signaling pathway.

Wang X, Li X, Ma X, Zhang L, Han T, Zhang D Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(6):4183-4194.

PMID: 38041777 DOI: 10.1007/s00210-023-02856-0.


Dihydromyricetin supplementation improves ethanol-induced lipid accumulation and inflammation.

Janilkarn-Urena I, Idrissova A, Zhang M, VanDreal M, Sanghavi N, Skinner S Front Nutr. 2023; 10:1201007.

PMID: 37680900 PMC: 10481966. DOI: 10.3389/fnut.2023.1201007.


Present Status, Challenges, and Prospects of Dihydromyricetin in the Battle against Cancer.

Wu J, Xiao Z, Li H, Zhu N, Gu J, Wang W Cancers (Basel). 2022; 14(14).

PMID: 35884547 PMC: 9317349. DOI: 10.3390/cancers14143487.


Dihydromyricetin Acts as a Potential Redox Balance Mediator in Cancer Chemoprevention.

Chen L, Shi M, Lv C, Song Y, Wu Y, Liu S Mediators Inflamm. 2021; 2021:6692579.

PMID: 33776577 PMC: 7979283. DOI: 10.1155/2021/6692579.


References
1.
Chan D, Watts G, Gan S, Wong A, Ooi E, Barrett P . Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity. Arterioscler Thromb Vasc Biol. 2010; 30(5):1043-50. DOI: 10.1161/ATVBAHA.109.202275. View

2.
Kim J, Song E, Lee H, Oh Y, Choi K, Yu D . HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. J Mol Biol. 2010; 397(4):917-31. DOI: 10.1016/j.jmb.2010.02.016. View

3.
Maraslioglu M, Weber R, Korff S, Blattner C, Nauck C, Henrich D . Activation of NF-κB after chronic ethanol intake and haemorrhagic shock/resuscitation in mice. Br J Pharmacol. 2013; 170(3):506-18. PMC: 3791990. DOI: 10.1111/bph.12224. View

4.
Li L, Hai J, Li Z, Zhang Y, Peng H, Li K . Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 2013; 63:166-73. DOI: 10.1016/j.fct.2013.08.036. View

5.
Huang H, Hu M, Zhao R, Li P, Li M . Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway. Oncol Rep. 2013; 30(5):2467-75. DOI: 10.3892/or.2013.2705. View